- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syntara Ltd (SNT)
Syntara Ltd stock price live, this page displays ASX SNT stock exchange data. View the SNT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Syntara Ltd real time stock price chart below.
What Is the Syntara Ltd Stock Price Today?
The Syntara Ltd stock price today is 0.026.
What Is the Stock Symbol for Syntara Ltd?
The stock symbol for Syntara Ltd is "SNT."
What Stock Exchange Does Syntara Ltd Trade On?
Syntara Ltd is listed and trades on the Sydney stock exchange.
Is Syntara Ltd a Good Stock to Buy?
Determining whether Syntara Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNT quote. (ISIN: AU0000312480)
What Is the Syntara Ltd Stock Price Today?
The Syntara Ltd stock price today is 0.026.
What Is the Stock Symbol for Syntara Ltd?
The stock symbol for Syntara Ltd is "SNT."
What Stock Exchange Does Syntara Ltd Trade On?
Syntara Ltd is listed and trades on the Sydney stock exchange.
Is Syntara Ltd a Good Stock to Buy?
Determining whether Syntara Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNT quote. (ISIN: AU0000312480)
Sydney
Currency in AUD
0.026
-0.001(-3.70%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.026
0.027
52 wk Range
0.019
0.040
SNT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0260.027
52 wk Range
0.0190.040
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
SNT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
0.105
Upside
+303.85%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.105
(+303.85% Upside)
Syntara Ltd Earnings Call Summary for Q4/2026
- Syntara raised AUD 8M via institutional placement, extending cash runway through H2 FY2028 amid positive FDA feedback on myelofibrosis program.
- FDA agreed on Phase IIb protocol for amsulostat in myelofibrosis; study requires $20-25M funding, targeting year-end start pending partner/investor.
- Shares rose 4.55% to $0.023 but remain near 52-week low; stock near bottom of $0.019-$0.066 range reflects cautious market sentiment.
- Multiple catalysts expected through 2028: full Phase II iRBD data, top-line hypertrophic scar results, interim keloid and MDS program data.
- CEO Phillips highlighted drug differentiation with earlier symptom improvement vs. competitors; funding discussions focus on mid-sized pharma partners.
Last Updated: 07/28/2026, 09:40 AM
Read Full TranscriptEarnings
Latest Release
Aug 27, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare SNT to Peers and Sector
Metrics to compare | SNT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −8.8x | −0.4x | |
PEG Ratio | 25.99 | 0.04 | 0.00 | |
Price/Book | 3.1x | 4.4x | 2.6x | |
Price / LTM Sales | 7.3x | 19.9x | 3.1x | |
Upside (Analyst Target) | 303.8% | 263.6% | 48.2% | |
Fair Value Upside | Unlock | 16.9% | 6.5% | Unlock |
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Syntara (SNT) Stock Price Today?
The Syntara stock price today is 0.026 AUD.
What Stock Exchange Does Syntara Trade On?
Syntara is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Syntara?
The stock symbol for Syntara is "SNT."
What Is the Syntara Market Cap?
As of today, Syntara market cap is 51.010M AUD.
What Is Syntara's Earnings Per Share (TTM)?
The Syntara EPS (TTM) is -0.006.
When Is the Next Syntara Earnings Date?
Syntara will release its next earnings report on Nov 03, 2026.
From a Technical Analysis Perspective, Is SNT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Syntara Stock Split?
Syntara has split 1 times.
What is the current trading status of Syntara (SNT)?
As of Aug 29, 2026, Syntara (SNT) is trading at a price of 0.026 AUD, with a previous close of 0.027 AUD. The stock has fluctuated within a day range of 0.026 AUD to 0.027 AUD, while its 52-week range spans from 0.019 AUD to 0.040 AUD.
What Is Syntara (SNT) Price Target According to Analysts?
The average 12-month price target for Syntara is 0.105 AUD, with a high estimate of 0.15 AUD and a low estimate of 0.06 AUD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +303.85% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.